- Step therapy requires trying a lower-cost medication before insurance approves a GLP-1
- Common step therapy medications: phentermine, Contrave, orlistat, metformin
- Most plans require 3–6 months of documented use
- PEAK documents everything during step therapy to build the strongest prior authorization case
- Step therapy isn’t a waste of time — these medications provide real benefit while building your case
- Some patients do well enough on step therapy medications that they don’t need a GLP-1
If your insurance plan requires step therapy before approving a GLP-1 like Wegovy or Zepbound, you are not alone. Step therapy is one of the most common barriers patients face when trying to access newer weight loss medications. But it does not have to be a frustrating roadblock. Here is how PEAK approaches step therapy strategically — so the process works for you, not against you.
What is step therapy?
Step therapy is an insurance requirement that asks you to try a less expensive medication first. If that medication does not produce adequate weight loss results, the documented evidence of that insufficient response supports approval for a more expensive medication — in this case, a GLP-1 receptor agonist like Wegovy (semaglutide) or Zepbound (tirzepatide).
This is not an arbitrary rule. It is how insurance companies manage costs for chronic conditions across the board. Similar step therapy requirements exist for cholesterol medications, blood pressure drugs, and diabetes treatments. The logic is straightforward: start with a proven, lower-cost option, and escalate if the clinical situation requires it.
Step therapy is not unique to weight loss. If you have ever been told to try a generic medication before your insurance would cover a brand-name drug, you have experienced step therapy. The same principle applies here — your plan wants documentation that a lower-cost option was tried before authorizing a higher-cost GLP-1.
Which medications count
Not every weight loss medication qualifies for step therapy with every plan. Requirements vary by insurer, but these are the four medications most commonly accepted as step therapy agents before GLP-1 approval.
Phentermine (typically low cost)
Phentermine is the most commonly accepted step therapy medication across insurance plans. It is a fast-acting appetite suppressant that has been FDA-approved since 1959 and is often compared to newer GLP-1 options like Zepbound. A typical course lasts 12 weeks — some plans accept one completed course, while others require a longer trial.
- Most widely accepted step therapy medication
- 12-week course; some plans accept one course, others require longer
- Fast-acting appetite suppressant with proven track record
- Very affordable — often the least expensive option
Contrave (variable by plan and pharmacy)
Contrave (naltrexone/bupropion) is widely accepted for step therapy and offers an important advantage: it can be used long-term, which gives you more time to build documentation. It targets cravings and reward-driven eating through a different mechanism than phentermine, making it particularly effective for patients whose eating is driven by emotional or habitual patterns rather than pure hunger.
- Widely accepted for step therapy across major insurers
- Can be used long-term, providing more documentation time
- Targets cravings and reward-driven eating
- Available in generic form at lower cost
Orlistat / Xenical / Alli (low to moderate cost)
Some plans accept orlistat as a step therapy medication. It works through a completely different mechanism — blocking fat absorption in the gut rather than suppressing appetite in the brain. Orlistat is available by prescription as Xenical or over the counter as Alli, though the OTC version may not count for all plans.
- Some plans accept orlistat for step therapy
- Different mechanism (fat absorption blocker)
- Available OTC as Alli — but the OTC version may not satisfy all plans
- Prescription Xenical is more commonly accepted
Metformin — off-label (typically low cost)
Some plans accept metformin for patients with insulin resistance or prediabetes. Metformin is not FDA-approved for weight loss, but it is well-established for metabolic health and has modest weight loss effects. It is extremely inexpensive and has a long safety record, which makes it a practical option when the plan accepts it.
- Some plans accept metformin for patients with insulin resistance
- Not FDA-approved for weight loss, but well-established for metabolic health
- Very inexpensive for most patients
- Long safety record spanning decades of clinical use
How long does step therapy take?
The duration of step therapy varies significantly by insurance plan. There is no universal standard — which is why PEAK verifies your specific plan requirements before starting any treatment. Here are the typical ranges we see:
- Minimum: 12 weeks. Some plans accept one completed phentermine course (12 weeks) as sufficient step therapy.
- Typical: 3–6 months. Most major insurance plans require 3 to 6 months of documented use of a step therapy medication.
- Some plans: 6–12 months. A smaller number of plans require 6 to 12 months, particularly for certain GLP-1 medications.
The key word in every requirement is documented. The time on a step therapy medication only counts if it is properly documented with clinical records — medication prescribed, dose, start and end dates, weight changes, side effects, and the clinical reason the medication was insufficient.
Before prescribing any step therapy medication, your PEAK clinician verifies your specific plan’s requirements. This includes the accepted medications, the required duration, and any documentation standards. We do not guess — we confirm, so your step therapy course counts the first time.
Why documentation matters
The quality of documentation during step therapy can make or break a prior authorization for a GLP-1. Insurance companies do not just want to know that you took a medication — they want to see a detailed clinical record that demonstrates the medication was tried, monitored, and ultimately insufficient for your needs.
At PEAK, we document every data point your insurance needs. This is not an afterthought — it is built into how we run every step therapy visit:
- Baseline weight, BMI, and comorbidities — documented at the start of step therapy
- Medication prescribed, dose, and start date — exact details that match what the plan requires
- Weight changes at each visit — tracked consistently to show the medication’s effect over time
- Side effects experienced — any adverse effects that limited the medication’s effectiveness or tolerability
- Reason the step therapy medication was insufficient — clinical language that addresses the plan’s criteria
- Clinical justification for GLP-1 — why the patient needs to escalate to a GLP-1 based on the documented step therapy outcome
At PEAK, we don’t just prescribe a step therapy medication and wait. We build the prior authorization case from day one — documenting every data point your insurance needs to approve a GLP-1.
PEAK’s step therapy strategy
We approach step therapy as an active treatment phase, not a waiting period. The goal is twofold: provide you with real treatment benefit during the step therapy period, and build the strongest possible prior authorization case for a GLP-1 if you need one.
Here is how our step therapy strategy works in practice:
- Verify exact plan requirements before prescribing. We contact your insurance and confirm which medications count, how long you need to take them, and what documentation standards apply.
- Choose the right step therapy medication. We select the medication that is most likely to help you clinically AND satisfy your specific plan’s requirements. These are not always the same thing — and when they differ, we optimize for both.
- Document clinical outcomes at every visit. Weight, vitals, side effects, medication adherence, and clinical assessment are recorded at every appointment during step therapy.
- Begin GLP-1 prior authorization paperwork before step therapy ends. We do not wait until your step therapy course is over to start the authorization process. We prepare the paperwork in advance so there is no gap between completing step therapy and starting a GLP-1.
- Provide real treatment benefit during the step therapy period. Step therapy medications work. Many patients lose meaningful weight during this phase. We treat it as genuine treatment, not a bureaucratic exercise.
- Appeal denials with thorough documentation. If a prior authorization is denied, our documentation gives us the strongest possible foundation for an appeal.
Many patients are surprised to learn that step therapy medications produce real results. Phentermine and Contrave are FDA-approved weight loss medications with meaningful clinical evidence behind them. Some patients do well enough on a step therapy medication that they decide not to transition to a GLP-1 at all — and that is a perfectly good outcome.
Frequently asked questions
What medications count for step therapy?
Common step therapy medications include phentermine, Contrave (naltrexone/bupropion), orlistat (Xenical/Alli), and sometimes metformin. Requirements vary by insurance plan — there is no universal list. At PEAK, we verify your specific plan’s requirements before starting treatment so you know exactly which medications count and how long you need to take them.
How long do I have to take a step therapy medication?
Most plans require 3–6 months of documented use. Some accept as little as 12 weeks (one full phentermine course), while others may require up to 12 months. PEAK documents your entire treatment course — weight changes, side effects, and clinical notes — to build the strongest prior authorization case possible.
What if the step therapy medication works?
If a step therapy medication produces satisfactory results, you may not need to transition to a GLP-1. At PEAK, we evaluate your response at regular intervals and only recommend a GLP-1 transition if the clinical situation warrants it. A step therapy medication that works well is a win — not a failure of the process.
Important safety information: Wegovy and Zepbound carry a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. They are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Contrave carries a boxed warning for suicidal thoughts and behavior. Discuss your full medical history with your clinician before starting any weight loss medication.
PEAK accepts commercial insurance and TRICARE. We do not accept Medicare or Medicaid, including Medicare Advantage and Medicaid managed care plans.
